Shukui Qin

Mar 14, 2024 | jamanetwork.com | Ryan Sun |Jose M. Moraleda |Lee-Jen Wei |Shukui Qin

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable HCC Shukui Qin, MD, PhD; Masatoshi Kudo, MD, PhD; Tim Meyer, MD, PhD; Yuxian Bai, MD; Yabing Guo, MD, PhD; Zhiqiang Meng, MD, PhD; Taroh Satoh, MD, PhD; Donatella Marino, MD; Eric Assenat, MD, PhD; Songzi Li, PhD; Yaxi Chen, MD; Frederic Boisserie, MSc; Ramil Abdrashitov, MD, PhD; Richard S.

Mar 14, 2024 | jamanetwork.com | Shukui Qin

Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma—Reply In Reply I thank and have provided responses to Sun et al for their comments on our article1 that compared tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma. The noninferiority margin of 1.08 is clearly clinically justifiable.

Oct 5, 2023 | jamanetwork.com | Shukui Qin |Masatoshi Kudo |Kindai Faculty |Tim Meyer

Key PointsQuestion  How does the efficacy and safety profile of tislelizumab compare with that of sorafenib as first-line treatment among patients with unresectable hepatocellular carcinoma (HCC)? Findings  In this phase 3 randomized clinical trial of 674 patients with HCC, tislelizumab demonstrated overall survival noninferiority compared with sorafenib, with numerically higher and more durable objective responses than sorafenib.

Sep 25, 2023 | futuremedicine.com | Do-Youn Oh |Aiwu Ruth He |Shukui Qin |Li-Tzong Chen

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original article hereAcknowledgmentsThis study was sponsored by AstraZeneca. We thank the participants in this study and their families, all the investigators and study site personnel, and the members of the independent data monitoring committee.

Jul 24, 2023 | thelancet.com | Shukui Qin |Stephen Chan |Shanzhi Gu |Yuxian Bai

1. Sung H Ferlay J Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-2492. Singal AG Lampertico P Nahon P Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020; 72: 250-2613. Llovet JM Ricci S Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-3904. Kudo M Finn RS Qin S et al.